98 related articles for article (PubMed ID: 26664472)
21. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
22. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM
Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
24. [Ultrasound involvement of the spleen in non-Hodgkin's lymphomas].
Görg C; Weide R; Schwerk WB
Ultraschall Med; 1995 Jun; 16(3):104-8. PubMed ID: 7667616
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
26. [Chronic viral hepatitis: current diagnosis and therapy].
Blum HE
Schweiz Rundsch Med Prax; 1993 Apr; 82(17):501-5. PubMed ID: 8493436
[TBL] [Abstract][Full Text] [Related]
27. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
28. Contrast enhanced ultrasound of splenic lymphoma involvement.
Görg C; Faoro C; Bert T; Tebbe J; Neesse A; Wilhelm C
Eur J Radiol; 2011 Nov; 80(2):169-74. PubMed ID: 20005061
[TBL] [Abstract][Full Text] [Related]
29. Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B: a case of HBV-associated lymphoma.
Koot AW; Visscher AP; Huits RM
Acta Clin Belg; 2015 Aug; 70(4):301-3. PubMed ID: 25977147
[TBL] [Abstract][Full Text] [Related]
30. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
31. [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
Kondo M; Kitada N; Kobayashi M; Morita S; Yoshioka M; Tsuji T; Mori A; Okamoto T; Watari M
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1199-201. PubMed ID: 19620818
[TBL] [Abstract][Full Text] [Related]
32. Splenic diffuse red-pulp small B-cell lymphoma associated with hepatitis B virus: a report of two cases.
Kerbauy MN; Fernandes CM; Bezerra ED; Lage LA; Siqueira SA; Pereira J
Sao Paulo Med J; 2016; 134(4):359-65. PubMed ID: 27581334
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
34. [Sonography in the diagnosis of lesions of abdominal lymph nodes, liver and spleen in malignant lymphoma].
Semenov II
Vopr Onkol; 1997; 43(2):198-201. PubMed ID: 9214122
[TBL] [Abstract][Full Text] [Related]
35. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
36. The relationship between splenic marginal zone B-cell lymphoma and chronic liver disease associated with hepatitis C virus infection.
Moccia F; Tognoni E; Boccaccio P
Ann Ital Med Int; 1999; 14(4):288-93. PubMed ID: 10638021
[TBL] [Abstract][Full Text] [Related]
37. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
38. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
39. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
40. Hepatosplenic T-cell lymphoma with coexistent hepatitis B infection: a rare clinicopathologic entity.
Siraj F; Dalal V; Khan AA; Jain D
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 26481866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
